
The CHMP of the EMA has issued a positive opinion recommending the marketing authorization of sintilimab plus pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with nonsquamous NSCLC. #lcsm #oncology onclive.com/view/sintilimab-…




